Retama

Lygos Announces Senior Leadership Appointments

Retrieved on: 
Friday, July 30, 2021
Alternative medicine, Agriculture, Health, Natural Resources, Genisteae, Retama, Trademark, Marketing, Market economics)

Lygos, Inc ., a vertically integrated provider of safe and sustainable specialty ingredients, today announced the leadership appointments of Bryce Dille as Chief Financial Officer and Nicholas Ohler, PhD, as Chief Technology Officer.

Key Points: 
  • Lygos, Inc ., a vertically integrated provider of safe and sustainable specialty ingredients, today announced the leadership appointments of Bryce Dille as Chief Financial Officer and Nicholas Ohler, PhD, as Chief Technology Officer.
  • Nicks proven track record of developing and scaling numerous fermentation-based processes has already helped to establish and build our technology leadership in the industry.
  • Lygos has created a full-stack biological engineering platform focused on organic acid specialty ingredients, health & wellness ingredients, including cannabinoids and bio-monomers.
  • Lygos and the Lygos logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos Achieves Commercial-Scale Production Capabilities for High-Quality Cannabinoids

Retrieved on: 
Wednesday, March 31, 2021
Alternative medicine, Agriculture, Health, Natural Resources, Intangible assets, Product management, Communication design, Articles, Academic disciplines, Branches of biology, Genisteae, Retama, Trademark, CBX, Logo, Brand, Lygos CBx, Lygos

After successfully transferring and piloting its novel fermentation-based production pathway, Lygos is now focused on running multiple production campaigns throughout 2021 to meet growing customer demand.

Key Points: 
  • After successfully transferring and piloting its novel fermentation-based production pathway, Lygos is now focused on running multiple production campaigns throughout 2021 to meet growing customer demand.
  • Lygos CBx bio-based production platform features quality control measures to ensure its products reproducibly meet high-quality standards with each batch and production site.
  • To date, internal production capabilities have allowed kilogram quantities of cannabinoid products to be developed, tested, and qualified for Lygos partners.
  • Lygos, Lygos CBx, and the Lygos and Lygos CBx logos are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos Joins Forces with Flexible Solutions to Meet Growing Commercial Demand for Bio-Aspartic™ Acid

Retrieved on: 
Tuesday, February 9, 2021
Alternative medicine, Engineering, Health, Chemicals, Plastics, Environment, Manufacturing, Biotechnology, Genisteae, Retama

Lygos, Inc ., a vertically integrated provider of safe and sustainable specialty ingredients, today announced a strategic investment from Flexible Solutions (NYSE: FSI) and its subsidiary NanoChem Solutions to advance Lygos Bio-Aspartic Acid technology.

Key Points: 
  • Lygos, Inc ., a vertically integrated provider of safe and sustainable specialty ingredients, today announced a strategic investment from Flexible Solutions (NYSE: FSI) and its subsidiary NanoChem Solutions to advance Lygos Bio-Aspartic Acid technology.
  • The investment is part of Lygos ongoing commitment to reducing dependence on foreign fossil fuels and reviving North American manufacturing capabilities.
  • Lygos aims to replace this toxic process by converting sustainable sugars into Bio-Aspartic Acid and other high-value specialty chemicals .
  • Lygos, the Lygos logo and Bio-Aspartic are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos CBx Adds Cannabichromene to Its Growing Portfolio of High-Quality, Pure and Sustainable Cannabinoids

Retrieved on: 
Tuesday, January 19, 2021
Chemicals, Plastics, Manufacturing, Biotechnology, Alternative medicine, Managed care, Health, Pharmaceutical, Agriculture, Natural Resources, Cannabinoid, Retama, CBX

CBC is the latest addition to the full Lygos CBx menu of highly pure and consistent cannabinoids for consumer and pharmaceutical applications.

Key Points: 
  • CBC is the latest addition to the full Lygos CBx menu of highly pure and consistent cannabinoids for consumer and pharmaceutical applications.
  • Lygos CBx utilizes its novel production pathway to provide a high-performance alternative to agricultural-based cannabinoid production.
  • Lygos CBx is a Lygos company focused on low-cost, industrial-scale production of a wide range of high-quality, pure and sustainable cannabinoid compounds that are not easily accessible through traditional agricultural means.
  • Lygos, Lygos CBx, the Lygos logo, and Lygos CBx logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos CBx and Metalabs Partner to Co-Develop and Commercialize Haircare Products Featuring Cannabinoids

Retrieved on: 
Thursday, December 17, 2020
Alternative medicine, Cosmetics, Retail, Health, Specialty, Biotechnology, Genisteae, Retama, Drugs, Cannabinoid, CBX, Tetrahydrocannabinol, Neurochemistry, Psychoactive drugs

Lygos CBx novel production pathway offers a high-performance, ultra-pure, THC-free, and consistent alternative to agricultural-based cannabinoid production.

Key Points: 
  • Lygos CBx novel production pathway offers a high-performance, ultra-pure, THC-free, and consistent alternative to agricultural-based cannabinoid production.
  • Together with Metalabs, we are poised to transform the traditional haircare products market with these new, cannabinoid-based natural supplements, said Eric Steen, PhD, CEO of Lygos.
  • Lygos CBx is a direct result of the recent NIH-funded Librede acquisition and integration of additional Lygos technology advances.
  • Lygos, the Lygos logo, Lygos CBx, and the Lygos CBx logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos and High Beauty Sign Agreement to Co-Develop and Commercialize Cosmetic Products Containing Rare Cannabinoids

Retrieved on: 
Monday, November 30, 2020
Alternative medicine, Cosmetics, Retail, Health, Specialty, Biotechnology, Asset, Intangible assets, Product management, Marketing, Cosmetics, Skin care, Retama, Trademark, Shoppers Drug Mart, Brand, Kohl, CBX, High Beauty, Lygos CBx, Lygos

High Beauty will work with Lygos CBx to accelerate the formulation and commercialization of co-branded cosmetic products based upon a wide range of high-quality, pure and naturally derived cannabinoids.

Key Points: 
  • High Beauty will work with Lygos CBx to accelerate the formulation and commercialization of co-branded cosmetic products based upon a wide range of high-quality, pure and naturally derived cannabinoids.
  • High Beauty sells its products through its organic online presence and at many of the leading beauty retailers, including Macys , Kohls , Douglas , Shoppers Drug Mart , The Shopping Choice , and Lookfantastic .
  • This partnership with the High Beauty team is a huge step forward in the beauty & cosmetic market for the Lygos CBx business.
  • Lygos, Lygos CBx, and the Lygos logo are trademarks of Lygos, Inc. High is a registered trademark of High Beauty, Inc. Any other brands may be trademarks of their respective holders.

Lygos Joins BioMADE Network to Advance Sustainable and Reliable Bioindustrial Manufacturing Technologies

Retrieved on: 
Tuesday, November 3, 2020
Technology, Pharmaceutical, Defense, Other Science, Other Energy, Environment, Research, Medical devices, Contracts, Energy, Biotechnology, Alternative medicine, Health, Science, Other Manufacturing, Textiles, Software, Packaging, Engineering, Chemicals, Plastics, Hardware, Automotive Manufacturing, Manufacturing, Articles, Genisteae, Retama, Innovation, the Engineering Biology Research Consortium, Lygos

Lygos, Inc. , a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has joined the Bioindustrial Manufacturing And Design Ecosystem (BioMADE), a nonprofit Manufacturing Innovation Institute (MII) and network of public-private entities created by the Engineering Biology Research Consortium (EBRC) .

Key Points: 
  • Lygos, Inc. , a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has joined the Bioindustrial Manufacturing And Design Ecosystem (BioMADE), a nonprofit Manufacturing Innovation Institute (MII) and network of public-private entities created by the Engineering Biology Research Consortium (EBRC) .
  • BioMADE is working together with Lygos and other manufacturers and innovators to advance bioindustrial manufacturing technologies while simultaneously enhancing the structure of the entire innovation ecosystem across the country.
  • BioMADE was recently awarded $87 million from the Department of Defense to promote and secure long-term US biotechnology innovation.
  • Lygos and the Lygos logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos Announces the Launch of Lygos CBx™, a New Low-Cost, Industrial-Scale Cannabinoid Production Company

Retrieved on: 
Monday, October 26, 2020
Alternative medicine, Health, Other Science, General Health, Research, Science, Genisteae, Retama, CBX, National Institutes of Health, Articles, Lygos CBx, Lygos

Lygos CBx is a result of the combination of Librede, the recently acquired NIH-funded biosynthetic company, and the integration of key Lygos technology advances.

Key Points: 
  • Lygos CBx is a result of the combination of Librede, the recently acquired NIH-funded biosynthetic company, and the integration of key Lygos technology advances.
  • View the full release here: https://www.businesswire.com/news/home/20201026005184/en/
    Lygos CBx utilizes its novel production pathway to provide a high-performance alternative to agricultural-based cannabinoid production.
  • Lygos CBx is a direct result of the recent NIH -funded Librede acquisition and integration of additional Lygos technology advances.
  • Lygos, Lygos CBx, Librede, and the Lygos and Lygos CBx logos are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos and Open Book Extracts Sign MOU to Co-Develop and Commercialize Nutraceutical Supplement Products Containing Rare Cannabinoids

Retrieved on: 
Tuesday, October 6, 2020
Software, Research, Pharmaceutical, Technology, Environment, Science, Chemicals, Plastics, Biotechnology, Other Technology, Manufacturing, Other Science, Health, Articles, Health, Cannabinoid, Trademark, Nutraceutical, Retama, Marketing

OBX and Lygos will incorporate CBG and its anti-inflammatory properties into a new line of nutraceutical supplement products to better serve the growing global demand for cannabinoid-enabled benefits.

Key Points: 
  • OBX and Lygos will incorporate CBG and its anti-inflammatory properties into a new line of nutraceutical supplement products to better serve the growing global demand for cannabinoid-enabled benefits.
  • We are excited to work with Lygos and leverage its proprietary cannabinoid production platform to make a line of innovative consumer products, said Dave Neundorfer, CEO of Open Book Extracts.
  • Lygos production technology now gives us access to any cannabinoid, even rare cannabinoids, which will enable us to enter new markets with high-quality products in the future.
  • Lygos, Librede and the Lygos logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.

Lygos Successfully Validates Novel Fermentation Process for Sustainable and Rare Cannabinoids

Retrieved on: 
Monday, August 17, 2020
Environment, Engineering, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Pharmaceutical, Other Science, Science, Brand management, Brands, Intellectual property law, Product management, Trademark, Cannabinoid, Retama, Marketing, Market economics), Microeconomics, Lygos, Librede

Librede , a wholly owned subsidiary of Lygos, had primarily operated on grants from the National Institutes of Health (NIH) prior to the Lygos acquisition.

Key Points: 
  • Librede , a wholly owned subsidiary of Lygos, had primarily operated on grants from the National Institutes of Health (NIH) prior to the Lygos acquisition.
  • The platform supports both ultra-rare and common cannabinoids, such as CBD, that feature compelling performance, economic and environmental advantages over traditional plant-based alternatives.
  • Libredes proprietary biochemistry platform allows for the production of natural compounds, particularly cannabinoids, in a highly efficient and sustainable manner.
  • Lygos, Librede and the Lygos logo are trademarks of Lygos, Inc. Any other brands may be trademarks of their respective holders.